Figure 11
From: RGN as a prognostic biomarker with immune infiltration and ceRNA in lung squamous cell carcinoma
Prediction of RGN-related drug responses in LUSC patients. (A) Prediction of the IC50 of common therapeutic agents in high- and low-RGN expression patients. (B) Distribution of RGN expression in CTLA4 or PD1 scores by TCIA database. (C) Distribution of RGN expression in TIDE, MSI, dysfunction and exclusion scores by TIDE database. ***P < 0.001; ns not significant.
